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Abstract. Neuropathological and biochemical findings are reported in a patient who had suffered from frontotemporal dementia
associated with a P310L mutation in thetau gene and included in the H1 haplotype.
Tau accumulation, as revealed with phospho-specific anti-tau antibodies Thr181, Ser199, Ser202, Ser214, Ser262, Ser396, Ser422
and AT8 (Ser202 and Thr205), was found in neurons with pre-tangles, and astrocytes and oligodendrocytes through the brain.
The most characteristic feature wast u immunoreactivity decorating the perinuclear region and small cytoplasmic aggregates
designed as mini-Pick-like bodies, mainly in the dentate gyrus. Inclusions were not stained with anti-ubiquitin antibodies and
did not recruit tubulins. Tau accumulation in individual cells was associated with increased expression of kinases linked withtau
phosphorylation, mainly active (phosphorylated) stress kinases SAPK/JNK and p38 (SAPK/JNK-P and p38-P). Phosphorylated
GSK-3β at Ser9 (GSK-3β-P), that inactivates the kinase, was particularly abundant in mini-Pick-like bodies, thus suggesting
alternative roles of GSK-3 probably involved in cell survival. Western blots of sarkosyl-insoluble fractions revealed a double band
pattern of phospho-tau of 68/66 kDa and 64 kDa in the hippocampus and white matter in the P310L mutation. Sarkosyl-insoluble
fractions of the hippocampus were enriched in p38-P and GSK-3β-P in Alzheimer’s disease (AD) cases, processed in parallel
for comparative purposes, but not in the P310L mutation. In addition, no bands of high molecular weight were found in P310L
in contrast with AD in these fractions. These findings indicate that the major sites ofau phosphorylation, and the expression of
kinases involved intau phosphorylation are active in P310L mutation as in AD and other tauopathies. Yet the P310L mutation
has particular phospho-tau inclusions that are not tag with ubiquitin and appear to be rather soluble when compared with AD.
1. Introduction
Tauopathies are neurodegenerative diseases charac-
terized by the abnormal hyper-phosphorylationand de-
position oftau in neurons and glial cells. Alzheimer’s
disease (AD), Pick’s disease (PiD), progressive supran-
uclear palsy, corticobasal degeneration and argy-
rophilic grain disease (AGD) are common tauopath-
ies [7,27,38–40]. In addition, the term frontotem-
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poral dementia and parkinsonism linked to chromo-
some 17 (FTDP-17) designates inherited tauopathies
associated with mutations in thetau gene [7,16,23,
27]. Tauopathies have been reproduced in transgenic
mice [17,22,28].
The P301L mutation is a common cause of famil-
ial tauopathy [1,6,26,31,33,36,37]. Like othertau mu-
tations in the binding region encoded by exon 10,
the P301L mutation greatly reduces the capacity to
promote microtubule assembly but results in abnor-
mal fibrillar aggregation [3,20,42]. Frontotemporal
atrophy with ballooned neurons in the frontal cor-
tex, widespreadtau-immunoreactive neurons and glial
cells, and a pattern of two bands of 66/68 kDa and
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64 kDa on Western blots have been observed in previous
cases [1,31,37]. In addition, some structural aspects of
tau phosphorylation in neurons and glial cells associ-
ated with the P301L mutation differ from one case to
another. Thus, neurofibrillary tangles, and astrocytic
plaques and tuft-like astrocytes appear to be common
in some cases but are rare in others [1,31,16]. This in-
dicates that, in addition to the common mutation, other
factors, including the haplotype, may influence the phe-
notype of the mutation [33]. Previous studies have
shown the P301L mutation in the H2 haplotype [41].
Interestingly, the presence of ubiquitin-negative, mu-
tatedtau-positive perinuclear reinforcements and small
cytoplasmic aggregates reminiscent of mini-Pick bod-
ies in neurons of selected areas, mainly granule cells
of the dentate gyrus, has been recently emphasized in
two patients with frontotemporal dementia bearing the
P301L mutation [1]. The P301L mutation has been
generated in two transgenic lines in mice [19,29,30].
In one line, Pick-like bodies are found in select brain
regions [29].
The present study focuses on theau deposits in neu-
rons in a new case of P301L tauopathy with particu-
lar attention totau phosphorylation and aggregation,
and to the local expression of kinases involved intau
phosphorylation.
2. Material and methods
2.1. Case report
The proband was a man who had suffered from dis-
turbances in social behavior starting at the age of 45
years, followed by intellectual impairment, language
disorder, difficulty in calculation but with preservation
of orientation and memory. The MRI carried out at the
age of 49 showed frontotemporal atrophy. The course
of the disease was progressive with apathy, irritabil-
ity, apraxia and epilepsy, together with marked loss of
language abilities. The patient died at the age of 52
years. His mother was affected by a similar disease; no
neurological examination and post-mortem study was
available.
The post-mortem delay between death and tissue
processing was 3 hours.
2.2. Genetic study
Exons of thetau gene were amplified by using
primers derived from 3′ and 5′ intronic sequences and
polymerasechain reaction (PCR) conditions previously
described [21] and analyzed through single strand con-
formation polymorphism (SSCP). After, electrophore-
sis, the gel was silver stained as described [4]. The
SSCP analysis of exon 10 indicated the presence of
an abnormal pattern in the proband when compared
with controls. The polymerase chain reaction (PCR)
product corresponding to the sample with the abnor-
mal SSCP pattern was sequenced using the ABIPRISM
Dye Terminator Cycle Sequencing Ready Reaction Kit
(Perkin–Elmer, Foster City, CA, USA) following the
manufacturer’s protocols and an automatic sequencer
(ABI PRISM model 377). The exon 10 sequence re-
vealed the presence of the P301L mutation in heterozy-
gosis in both, the sense and the complementary strand.
Tau haplotype H1/H1 was determined genotyping one
of the polymorphism previously described [10].
2.3. Neuropathological study
The neuropathological examination was carried out
in formalin-fixed tissue for no less than three weeks;
the tissue was then embedded in paraffin. De-waxed
sections, 5µm thick, were stained with haematoxylin
and eosin, and luxol fast blue-Klüver Barrera or pro-
cessed for immunohistochemistry following the strep-
tavidin LSAB method (Dako, Dakopats, Barcelona,
Spain). After incubation with methanol and normal
serum, the sections were incubated with one of the pri-
mary antibodies at 4◦C overnight. Antibodies to phos-
phorylated neurofilaments of 170 kD or 200 kD (clones
BF10 and RT97, Boehringer-Mannheim, Barcelona,
Spain) were used at dilutions of 1:100 and 1:50, re-
spectively. Antibodies to glial fibrillary acidic protein
(GFAP, Dako),βA4-amyloid (Boehringer-Mannheim),
and ubiquitin (Dako) were used at dilutions of 1:250,
1:5, and 1:200, respectively. Antibodies toα-synuclein
(Dako) were used at a dilution of 1:100. Antibodies
to pan-tau (Sigma, Madrid, Spain) were used at a di-
lution of 1:10. In addition, the following phospho-
specific tau rabbit polyclonal antibodies were used:
Thr181, Ser199, Ser202, Ser214, Ser231, Ser262,
Ser396 and Ser422 (all of them from Calbiochem,
VWR, Barcelona, Spain). The antibodies were used at
a dilution of 1:100, excepting anti-phospho-tauThr181,
which was used at a dilution of 1:250. The monoclonal
antibody AT8 (Dr. J. Avila), that recognizestau pro-
tein phosphorylated at both Ser202 and Thr205 [17]
was used at a dilution of 1:200. Monoclonal antibod-
ies toα-tubulin (Neomarkers, Molecular Probes, Lei-
den, The Netherlands) and rabbit polyclonal antibodies
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to β2-tubulin (Dr. J. Avila) were used at dilutions of
1:100 and 1:500, respectively. Following incubation
with the primary antibody, the sections were incubated
with LSAB for 1 h at room temperature. The peroxi-
dase reaction was visualized with 0.05% diaminoben-
zidine and 0.01% hydrogen peroxide. Sections were
counterstained with haematoxylin. Sections processed
for phospho-tau immunohistochemistry were boiled in
citrate buffer prior to the incubation with the primary
antibody. Sections processed forβA4-amyloid andα-
synuclein were pre-treated with 95% formic acid.
2.4. Kinase immunohistochemistry
Sections were processed with the streptavidin LSAB
method, as previously. Sections were boiled in citrate
buffer and then processed for immunohistochemistry.
The anti-MAP kinase phospho-specific (MAPK/ERK-
P) rabbit polyclonal antibody (Calbiochem) is raised
against a synthetic phospho-tyrosine peptide corre-
sponding to residues 196–209 of human p44 MAP ki-
nase. The antibody detects phosphorylated Tyr204
of p44 and p42 MAP kinases (phospho-ERK1 and
ERK2). The purified phospho-p38 MAP kinase
(Thr180/Tyr182) (p38-P) rabbit polyclonal antibody
(Cell Signaling, Izasa, Barcelona, Spain) detects p38
MAP kinase only when activated by dual phospho-
rylation at Thr180 and Tyr182. The purified rabbit
polyclonal phospho-SAPK/JNK (Thr183/Tyr185) an-
tibody (SAPK/JNK-P) (Cell Signaling) is produced
against a synthetic phospho-Thr183/Tyr185 peptide
corresponding to the residues of human SAPK/JNK.
The antibody detects SAPK/JNK only when activated
by phosphorylation at Thr183/Tyr185. The antibodies
to MAPK/ERK-P and SAPK/JNK-P were used at a di-
lution of 1:100. The antibody to p38-P was used at a di-
lution of 1:200. The anti-GSK-3α/β monoclonal anti-
body (StressGen, Bionova, Madrid, Spain) reacts with
51 and 47 kDa proteins corresponding to the specific
molecular weight of GSK-3α and GSK-3β. The anti-
body was used at a dilution of 1:100. The anti-phospho-
specific GSK-3βSer9 antibody (Oncogene, Bionova,
Madrid, Spain) is a rabbit polyclonal IgG antibody spe-
cific for the Ser9 phosphorylated form of glycogen syn-
thase kinase-3β. The antibody was used at a dilution
of 1:100.
2.5. Biochemical study
For gel electrophoresis and Western blotting, fresh
samples of the P301L mutation were immediately ob-
tained at autopsy, frozen in liquid nitrogen, and stored
at −80◦C until use. For comparative purposes, fresh
hippocampal samples of four patients with Alzheimer’s
disease stage V of Braak and Braak, with similar post-
mortem delays (between 2 and 5 h), were processed in
parallel.
Fresh samples from the hippocampus and white mat-
ter (about 5 g) were homogenized in a glass tissue
grinder in 10 vol (w/v) of cold suspension buffer con-
sisting of 10 mM Tris-HCl (pH=7.4), 0.8 M NaCl,
1 mM EGTA, 10% sucrose, 0.1 mM phenylmethylsul-
fonyl fluoride, 2µg/ml aprotinin, 10µg/ml leupeptin
and 5µg/ml pepstatin. The homogenates were first
centrifuged at 20,000× g, and the supernatant (S1)
was retained. The pellet (P1) was re-homogenized in 5
vol of homogenization buffer and re-centrifuged. The
two supernatants (S1+S2) were then mixed and incu-
bated with N-lauroylsarcosynate 1% for 1 h at room
temperature while shaking. Samples were then cen-
trifuged for 1 h at 100,000× g in a Ti 70 Beck-
man rotor. Sarkosyl-insoluble pellets (P3) were re-
suspended (0.2 ml per g of starting material) in 50 mM
Tris-HCl (pH=7.4). Protein concentrations were de-
termined by the BCA method and 10% sodium dode-
cyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) was run using a maxi-protean system (Bio-Rad,
Madrid, Spain). 100–200µg of protein was loaded in
each lane with loading buffer containing 0.125 M Tris
(pH=6.8), 20% glycerol, 10% mercaptoethanol, 4%
SDS and 0.002% bromophenol blue. Samples were
heated at 95◦C for 5 min prior to gel loading. Total
homogenates and fractions enriched with abnormal fil-
aments were run in parallel. The proteins were then
transferred to nitrocellulose membranes (Amersham)
using an electrophoretic chamber system (Trans-Blot
Electrophoretic Transfer Cell, Bio-Rad). Non-specific
binding sites were blocked with Tris-buffered saline so-
lution pH=7.4 with 0.1% Tween-20 (TBST) contain-
ing 5% skimmed milk for 30 min, and incubated with
one of the primary antibodies for 1 h at room temper-
ature. Control of protein content in each lane was car-
ried out by the staining of selected gels with Coomassie
blue and of the membranes with Ponceau (Sigma). The
rabbit polyclonal antibody to phospho-tauThr181 was
diluted 1:250. The rabbit polyclonal antibodies anti-
phospho-tauSer262 andSer422 (all from Calbiochem)
were used at a dilution of 1:1500. The p38-P antibody
(Cell Signaling) was used at a dilution of 1:200. The
anti-GSK-3βSer9 antibody (Oncogene) was used at a
dilution of 1:100. After washing, the membranes were
incubated with the secondary antibody labeled with
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horseradish peroxidase (Dako) diluted 1:1000 for 1 h at
room temperature, washed again, and developed with
the chemiluminescence ECL Western Blotting system
(Amersham, Barcelona, Spain). Membranes were then
exposed to autoradiographic films (Hyperfilm ECL,
Amersham).
3. Results
3.1. General neuropathological findings
The macroscopical examination revealed moderate
atrophy of the brain (1300 g) predominating in the
frontal and temporal lobes, and striatum and slight at-
rophy of the thalamus. The cerebellum and brain stem
were normal with the exception of slight pallor in the
substantia nigra.
The microscopic study showed severe neuron loss
and increased numbers of astrocytes in the cerebral cor-
tex, and spongiosis in the upper layers predominating
in the frontal and temporal lobes (Fig. 1 A). Ballooned
neurons filled with phosphorylated neurofilaments and
containingαB-crystallin were common in the frontal
cortex (Fig. 1 B). The hippocampus and the dentate
gyrus were best preserved in haematoxylin and eosin-
stained sections, although pale cytoplasmic inclusions
were seen in a few granule cells (Fig. 1 C). Slight neu-
ron loss and astrocytic gliosis were present in the stria-
tum, amygdala and substantia nigra. Slight myelin pal-
lor, together with astrocytic gliosis, was found in the
centrum semi-ovale. Noα-synuclein inclusions and
βA4-amyloid deposits were found.
Sections stained with anti-tau antibodies disclosed
the presence oftau accumulation in neurons in the up-
per and inner layers of the cerebral neocortex (Fig. 2
A), entorhinal cortex (Fig. 2 B), subiculum and cel-
lular layer of the hippocampus (Fig. 2 C), thalamus,
subthalamus, striatum (Fig. 2 D), dentate gyrus (Fig. 2
E), amygdala and Meynert nucleus (Fig. 2 E), among
other gray nuclei. Interestingly,tau deposition in the
cerebral cortex displayed a peculiar pattern involving
layer II/III and layer V neurons. The majority of
neurons were pre-tangles, whereas neurofibrillary tan-
gles were very rare. The most characteristic finding
was tau-immunoreactivity decorating the perinuclear
region and, particularly, small cytoplasmic aggregates
resembling mini-Pick-like bodies. Mini-Pick-like bod-
ies were most common in the dentate gyrus (Fig. 2
E) but were seldom encountered in the cerebral cor-
tex (Fig. 2 B) and deep cerebral nuclei (Fig. 2 E). A
few tau-immunoreactesubstantia nigra, locus ceruleus,
periaqueductal and periventricular nuclei, and reticular
formation of the brain stem. In addition to neurons,
tau-immunoreactive astrocytes were found in the cere-
bral cortex (Fig. 2 G and H). Astrocytic plaques were
seen in the frontal cortex but not in the hippocampus
and dentate gyrus. Tuft-like astrocytes were absent.
Oligodendroglial inclusions, some of them reminiscent
of coiled bodies, were abundant in the white matter
(Fig. 2 I).
Tau-immunoreactive inclusions in neurons and glial
cells were examined with antibodies to phospho-tau.
Similar findings were found with the phospho-specific
anti-tau antibodies AT8, and Thr181, Ser199, Ser202,
Ser214, Ser262, Ser396 and Ser422. Pre-tangles, per-
inuclear halos and cytoplasmic neuronal aggregations
designed as mini-Pick-like bodies were equally im-
munostained. Interestingly, the vast majority of gran-
ular neurons in the dentate gyrus were stained with
anti-phospho-tau antibodies: more than a half con-
tained mini-Pick-like bodies. Yet pre-tangles andtau-
immunoreactive inclusions, including mini-Pick-like
bodies, were not stained with anti-α-tubulin and anti-
β-tubulin antibodies. Mini-Pick-like bodies, and the
vast majority of neurons, excepting rare neurofibrillary
tangles, were not stained with anti-ubiquitin antibodies
(data not shown).
3.2. Phospho-kinase immunoreactivity
Neuronal immunostaining was rarely observed with
anti-MAPK/ERK-P antibodies. Yet, small punctate
SAPK/JNK-P-immunoreactive cytoplasmic granules
were present in about 1/3 of granular neurons in the
dentate gyrus (Fig. 3 A, C). Immunoreactivity to p-38-
P was observed in more than a half of dentate gyrus
granular neurons (Fig. 3 A, D), and in many cortical
and CA1 pyramidal neurons with pre-tangles (Fig. 3 B,
E). No differences in GSK-3α/β immunostaining was
found between neurons with and without abnormaltau
deposits (data not shown). Mini-Pick-like bodies were
decorated with anti-GSK-3β-P antibodies (Fig. 3 F).
However, GSK-3β-P was rarely encountered in neu-
rons with no mini-Pick-like bodies, including those of
the frontal and temporal neocortex.
3.3. Biochemical studies
Biochemical studies of total homogenates and
sarkosyl-insoluble fractions disclosed a pattern of two
bands of phospho-tau of 68/66 kDa and 64 kDa in the
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Fig. 1. Marked loss of neurons and spongiosis of the upper layers in the frontal cortex (A). This is accompanied by ballooned neurons containing
?B-crystallin (B). No apparent cell loss occurs in the dentate gyrus although a few granule cells contain pale small cytoplasmic inclusions (D,
arrow). Paraffin sections; CC: cerebral cortex; DG: dentate gyrus. A, bar= 25 µm. B and C, bar inC = 10 µm.
Fig. 2. Tau-immunoreactive neurons are seen in the frontal cortex (A), entorhinal cortex (B), CA1 area of the hippocampus (C), striatum (D),
dentate gyrus (E) and Meynert nucleus (F). Mosttau-immunoreactive neurons are pre-tangles showing perinuclear immunoreactive halos and
cytoplasmic small inclusion roughly resembling mini-Pick bodies, which are particularly abundant in neurons of the dentate gyrus. In addition,
tau-immunoreactive astrocytes are found in the cerebral cortex (G, H), andtau-immunoreactive oligodendrocytes in the white matter (I). Paraffin
sections slightly counterstained with haematoxylin. CC: cerebral cortex; EC: entorhinal cortex; CA1: area of the hippocampus; str: striatum;
DG: dentate gyrus; Mey: Meynert nucleus; As: astrocytes; WM: white matter. Bar= 10 µm.
hippocampus and white matter. The same results were
obtained with the antibodies to phospho-tauThr181,
phospho-tauSer262 and phospho-tauSer422 (Fig. 4).
Kinase expression in the hippocampus was exam-
ined in parallel in AD and P301L mutation for com-
parative purposes. Sarkosyl-insoluble fractions in AD,
but not in P301L, were enriched in p38-P and GSK-
3β-P. Moreover, p38-P-immunoreactive bands of high
molecular weight were not found in the P301L mu-
tation. Finally, the largest amount of GSK-3β-P was
found in the sarkosyl-insoluble fraction in AD (Fig. 5).
4. Discussion
Tau accumulation in the patient with a P301L mu-
tation in thetau gene and included in the H1 haplo-
type was found in neurons with pre-tangles, and astro-
cytes and oligodendrocytes through the brain. The most
characteristic feature wastau immunoreactivity deco-
rating the perinuclear region and small cytoplasmic ag-
gregates designed as mini-Pick-like bodies, mainly in
the dentate gyrus. Similar inclusions were reported in
seminal cases [31] and have been recently examined by
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Fig. 3. Mini-Pick-like bodies in the dentate gyrus (A) and pre-tangle neurons in the hippocampus (B) are associated with small punctate
SAPK/JNK-P (C) and p38-P (D and E) cytoplasm inclusions. A number of mini-Pick bodies are also stained with anti-GSK-3β-P antibodies (F).
Paraffin sections, slightly counterstained with haematoxylin. Bar= 10 µm.
Adamec et al. [1]. Perinucleartau-positive immunorec-
tivity also occurs in FTDP-17 with a P301S mutation
in thetau gene [8]. Pick-body-like neuronal inclusions
have also been found in association with a G389R mu-
tation in thetau gene in the context of FTDP-17 [36].
The sites oftau phosphorylation, as seen by using a
panel of phospho-specific anti-tau antibodies, are sim-
ilar in P301L tauopathy and other sporadic and fa-
milial tauopathies [11,15]. Phosphorylation sites in-
clude Thr181, Ser199, Ser202, Ser214, Ser262, Ser396
and Ser422, and those recognized by the antibody AT8
(Ser202 andThr205). The present results have shown
increased SAPK/JNK-P and p-38-P expression in asso-
ciation with tau deposits, whereas only a few neurons
have been stained with the anti-MAPK/ERK-P anti-
bodies. Phosphorylation oftau in the P301L mutation
probably depends on the same kinases that phosphoy-
latetau in other tauopathies, including Alzheimer’s dis-
ease, progressive supranuclear palsy, corticobasal de-
generation, Pick’s disease, argyrophilic grain disease
and FTDP-17 [2,11–15,25,34,35,43–45]. Therefore, it
is reasonable to conclude that mutatedau facilitates
tau phosphorylation through a mechanism that is com-
mon to other tauopathies. In addition, GSK-3β PSer9
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Fig. 4. Western blots of sarkosyl-insoluble fractions of the white matter and hippocampus showing a pattern of two bands of 68/66 kDa and
64 kDa by using phospho-specific anti-tau antibodies Thr181, Ser262 and Ser422.
is present in neurons and glial cells in sporadic and
familial tauopathies [11,12,15,34]. It is interesting to
note that GSK-3β-PSer9 decorates a few neurons in
the cerebral cortex but the majority of neurons with
mini-Pick-like bodies in the dentate gyrus in the P301L
mutation. Phosphorylation of GSK-3β at Ser9 inacti-
vates the kinase and then the capacity to phosphorylate
substrates, but GSK-3β-PSer9 also prevents cell death
by apoptosis in several paradigms [9]. It is feasible that
multiple signals can be triggered by GSK-3 depending
on the state and site of phosphorylation [5,24]. Gran-
ule cells in the dentate gyrus are largely preserved in
number whereas neurons in the upper neocortical layers
are devastated. It is tempting to speculate that neurons
expressing GSK-3β-PSer9 are best equipped to cancel
cell death programs in P301L tauopathy.
Although phosphorylation sites intau and expression
of kinases in target cells kinases are similar in the P301L
mutation and other sporadic and familial tauopathies, it
is important to note thattau deposits differ from those
encountered in AD and PiD. A major point is the lack
of staining with anti-ubiquitin antibodies in the vast
majority of tau-containing neurons, excepting the few
with neurofibrillary tangles, and the lack of ubiquitina-
tion of the perinuclear halo and mini-Pick-like bodies
in P301L tauopathy, as previously stressed by Adamec
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Fig. 5. Western blots of sarkosyl-insoluble (PHF) fractions and total homogenates of the hippocampus in Alzheimer’s disease (AD) and P310L
mutation. Results in AD are representative of four cases. Sarkosyl-insoluble fractions in AD are enriched in p38-P and GSK-3β-PSer9. Several
bands of high molecular weight, reminiscent of those of phospho-tau in PHF fractions are seen in AD but not in the P310L mutation.
et al. [1]. Abnormaltau deposition in neurons is neither
associated with abnormal accumulation ofα-tubulin
andβ-tubulin, as occurs in neurofibrillary tangles in
AD and Pick bodies in PiD. These findings further sup-
port the notion of structural differences between neu-
ronaltau inclusions in AD and PiD, and P301L tauopa-
thy. Pre-tangle neurons that are a characteristic fea-
ture in AGD are not ubiquitinated and do not recruit
β-tubuline with this observation, p38-P and GSK-3β P
are enriched in sarkosyl-insoluble fractions in AD, but
not in the P310L mutation. Moreover, p38-P bands of
high molecular weight indicating either the formation
of aggregates or abnormal cross-reaction with phospho-
tau do occur in AD, but not in P310L mutation. Finally,
higher GSK-3β-P expression is found in the sarkosyl-
insoluble fraction in AD whereas the contrary occurs in
P310L mutation. Interestingly, the pattern of kinases in
subcellular fractions in P310L mutation resembles that
found in argyrophilic grain disease [11] in which, in ad-
dition to grains, pre-tangles rather than tangles are the
major pathological abnormality. Together these results
point to differences in solubility oftau and associated
kinases in P310L mutation when compared with AD.
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